Key Points {#FPar1}
==========

The efficacy and safety of the bactericidal antibiotic VB-1953 (2%) topical gel was evaluated for acne treatment in an investigator-initiated, open-label, single-arm study in acne patients who did not respond to or showed poor response to previous clindamycin treatment and had clindamycin-resistant *Cutibacterium acnes*.In the era of emerging antimicrobial resistance, the selection of VB-1953 for acne treatment can play a key role in improving clinical outcomes in acne patients and in public health.

Introduction {#Sec1}
============

Acne vulgaris is a chronic inflammatory skin disease that is predominant in late childhood and adolescence but can occur at any age and can persist well into adulthood \[[@CR1]--[@CR3]\]. The clinical features of acne include seborrhoea, inflammatory (pustules, papules, nodules or cysts) and noninflammatory lesions (open and closed comedones), as well as scarring in severe cases \[[@CR3]--[@CR5]\]. Although there are many facets of acne pathogenesis, one of the key etiological factors in its development is Gram-positive *Cutibacterium acnes* (*C. acnes*) \[[@CR6]\]. The host response to *C. acnes* can result in the production of various proinflammatory cytokines, including tumour necrosis factor (TNF)-α and several interleukins (ILs) such as IL-1, IL-6, IL-8 and IL-12 \[[@CR7]--[@CR9]\]. *C. acnes* activates toll-like receptor (TLR)-2 for triggering host-mediated inflammation, which in turn modulates the nuclear factor-kappa B (NF-κB) pathway \[[@CR8], [@CR10]\]. Furthermore, proteases secreted from *C. acnes* induce protease-activated receptor (PAR)-2, which leads to the release of IL-8 and matrix metalloproteinases (MMPs) from keratinocytes \[[@CR11]\]. In macrophages, *C. acnes*-stimulated reactive oxygen species (ROS) can induce the expression of inducible nitric oxide synthase and cyclooxygenase-2/prostaglandin E2 (COX-2/PGE2) during acne infection \[[@CR12]\]. Moreover, literature reports indicate that in human sebocytes, *C. acnes* stimulates the NLRP3 infammasome, which regulates the maturation and secretion of IL-1β via caspase-1 activity \[[@CR13]\]. Antibiotics are the first choice of treatment for mild-to-moderate, mixed, papular/pustular, and moderate nodular acne, and an alternative choice in severe, nodular/conglobate acne \[[@CR14], [@CR15]\]. The widespread use of oral and topical antibiotics such as macrolides, lincosamides and tetracyclines to treat acne, sometimes for extensive periods, has led to the worldwide emergence of *C. acnes* strains resistant to these antibiotics \[[@CR16]--[@CR18]\].

Multiple studies reporting the detection of resistant isolates of *C. acnes* were published in different parts of the world \[[@CR19]--[@CR21]\]. In the US, resistance to clindamycin has evolved to a staggering one in three patients carrying resistant strains of *C. acnes* \[[@CR17]\]. Clindamycin-resistant *C. acnes* were classified into different classes based on the point mutations observed in the 23S ribosomal RNA (rRNA) gene of *C. acnes*, i.e. A2058G (class I), A2059G (class IV) and G2057A (class III) \[*Escherichia coli* equal numbering\] \[[@CR22], [@CR23]\]. The mechanism of drug resistance in phenotype class II is mediated by the ermX gene present in the mobile genetic element, transposon TN5432 of *Corynebacterial* origin \[[@CR24]\], while tetracycline resistance is mediated by point mutation G1058C in 16S rRNA of *C. acnes* \[[@CR25]\].

The present treatment guidelines recommend antibiotics in combination with other antibacterials to achieve disease control by attaining maximal outcome in the management of inflammatory and noninflammatory acne, as well as to avoid resistance development \[[@CR26], [@CR27]\]; however, this regimen may only be partially effective in cases of patients harboring resistant strains \[[@CR18]\]. This challenging situation demands the development of new antibiotics with potent bactericidal action against *C. acnes* and additionally exhibiting anti-inflammatory properties.

We developed a novel topical gel formulation of VB-1953 (2%), a fourth-generation fluroquinolone, effective against *C. acnes*. Fluoroquinolones are known to interfere with the activities of enzymes, DNA gyrase and topoisomerase IV, essential for bacterial DNA replication \[[@CR28]\]. A fluoroquinolone-based anti-acne drug, nadifloxacin, having bactericidal action against *C. acnes*, is approved in parts of Europe and Japan for acne treatment \[[@CR29], [@CR30]\]. One of our previous reports has shown potent *in vitro* activity of VB-1953 against clinical isolates of *C. acnes* with diverse resistance spectrum (mutations in either A2058G or A2059G \[*E. coli* numbering\] in bacterial 23S rRNA) to clindamycin and erythromycin \[[@CR18]\]. Recently, the VB-1953 formulation resulted in a significant reduction of inflammatory lesions after 12 weeks of application of the formulation in patients with moderate to severe acne in a proof-of-concept randomised trial \[[@CR31]\]. Additionally, the formulation was found to be safe and well tolerated in humans. Based on these observations, we rationalised that VB-1953 could emerge as a novel treatment for inflammatory acne in patients carrying clindamycin-resistant *C*. *acnes* and not responding to clindamycin treatment.

Methods {#Sec2}
=======

Study Participants {#Sec3}
------------------

Healthy male or non-pregnant females aged between 18 and 45 years with a clinical diagnosis of acne vulgaris of moderate to severe grade (grade 3 or 4 as determined by the Investigator's Global Assessment \[IGA\]) were included in this study. Subjects had at least 20 inflammatory lesions (papules, pustules and nodules/cysts) and at least 20 noninflammatory lesions (open/closed comedones) on the face. Subjects with more than two facial nodulocystic lesions, active nodulocystic acne, and any skin condition or disease interfering with evaluation were excluded. Furthermore, all subjects enrolled in the study had undergone topical clindamycin or clindamycin fixed-dose combination (FDC) treatment in the past month, did not or poorly responded to clindamycin treatment, and harbored clindamycin-resistant *C. acnes* strains. Moreover, subjects with serious clinical illness or chronic diseases, and subjects who had taken certain topical or systemic anti-acne treatments that, in the opinion of the investigator, may interfere with the study, were not included. The inclusion and exclusion criteria for subject recruitment are described in detail in the electronic supplementary Methods, Sect. 1.1.

Study Design {#Sec4}
------------

This was an open label, non-randomised, prospective clinical study evaluating the safety, tolerability and efficacy of VB-1953 in adult subjects with moderate to severe facial acne vulgaris who did not respond, or had low response, to clindamycin treatment. On Visit 1, an initial screening was performed, followed by collection of a bacterial swab from the patient's face, as mentioned in Sect. [2.5](#Sec7){ref-type="sec"}. Thereafter, microbiological testing was performed to check the presence of clindamycin-resistant strains in the samples collected. Of the 80 patients screened, samples from 19 subjects were positive for the above strains, which called for further follow-up visits. On Visit 2, the 19 subjects were enrolled into the study and were assessed for baseline IGA, lesion counts (inflammatory and noninflammatory) and local skin reactions (LSRs). Subjects were instructed to apply VB-1953 (2%) gel on the entire face twice daily for 12 weeks. Visit 2 was then followed by three subsequent visits, i.e. Visits 3, 4 and 5, corresponding to 4, 8 and 12 weeks after Visit 2, respectively. Furthermore, acne swab samples from enrolled patients were collected on Visit 3 (week 4) and Visit 5 (week 12) for microbiology testing.

The study was approved by the Independent Ethics Committee (Good Society of Ethical Research \[GSER\], Delhi, India) and was conducted as per Schedule Y (amended version, 2005) of the Central Drugs Standard Control Organization (CDSCO), Ministry of Health and Family Welfare, Government of India; 'Ethical Guidelines for Biomedical Research on Human Participants' (2006); Indian Council of Medical Research (ICMR)\]; International Conference on Harmonization (ICH) E6--(R1) 'Guideline for Good Clinical Practice'; and Declaration of Helsinki (2013). Study-related procedures were initiated only after obtaining written informed consent from all the subjects.

Study Treatment and Outcome Measurements {#Sec5}
----------------------------------------

All subjects applied VB-1953 topical gel (2%) twice daily (in the morning and evening) for 12 weeks, and were encouraged to report any adverse incidences that happened during the study period. Safety was assessed by evaluation of local and systemic adverse events (AEs) and physical examination. The LSRs of erythema, edema, and scaling/dryness were estimated using a 5-point scale, and the LSRs of stinging/burning and pruritus/itching were estimated using a 4-point scale \[[@CR32]--[@CR34]\].

Efficacy was determined by acne lesion counts (inflammatory and noninflammatory lesions) and the IGA of overall acne severity (a 5-point static scale). Analysis as per the statistical analysis plan was conducted on the following parameters: (1) absolute change in inflammatory lesions from baseline to week 12; (2) absolute change in noninflammatory lesions from baseline to week 12; (3) proportion of subjects with IGA success.

The presence of clindamycin-resistant *C. acnes* in the acne swab samples collected from patients was checked and quantitated by microbiology and molecular biology testings.

Study Analyses {#Sec6}
--------------

All statistical processing was performed using R software (The R Foundation for Statistical Computing, Vienna, Austria). Summary tables (descriptive statistics and/or frequency tables) were prepared for baseline, efficacy and safety variables. Continuous variables were described using descriptive statistics (mean, median, standard deviation, minimum and maximum), and the frequency counts and percentage of subjects within each category were provided for categorical data. *P* values \< 0.05 were considered descriptive and no adjustments were made for multiple comparisons. Descriptive statistics were used to summarise compliance for the safety population. Measures of compliance included the duration of treatment (days) and the total number of applications. The efficacy endpoints, and the absolute change from baseline in inflammatory and noninflammatory lesion counts at week 12, were analysed using the paired *t* test. The proportion of subjects with IGA success was analysed using the Cochran--Mantel--Haenszel (CMH) test for general association stratified by site.

AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding dictionary and summarised according to relationship to the test article, and severity. Changes in physical examination, vital signs (temperature, blood pressure, pulse rate and respiration rate) were summarised using descriptive statistics. The analysis of safety was conducted on the safety population.

Detection of Clindamycin-Resistant *Cutibacterium acnes* in Acne Lesions of Patients {#Sec7}
------------------------------------------------------------------------------------

### Swab Collection {#Sec8}

Swab samples were collected from three places on the subject's face, following previously described detergent scrub/swab methods with modifications \[[@CR35]\]. To remove the aerobic bacteria and dirt on the surface, the volunteer's forehead and cheeks were cleaned by thoroughly wiping the area for 30 s with sterile gauze soaked in 0.1% Triton-X-100. By holding the sterile plastic ruler and marker, the sampling area (16 cm^2^ \[4/4 cm\]) was marked in three places on the face (left cheek, right cheek and forehead). The swab sample was collected from all three places by rubbing the moistened sterile cotton swab for 30 s. All three cotton swabs were transferred, one after the other, into a sterile falcon tube containing 2 mL of sterile fluid thioglycolate broth, and the bacterial content was released by squeezing the cotton swab tip against the falcon tube wall. Samples were brought to the microbiology laboratory as early as possible to analyse the presence of *C. acnes*/drug-resistant *C. acnes* by conventional microbiology and molecular biology assays.

### Microbiology Culture-Based Identification of Clindamycin-Resistant*C. acnes* {#Sec9}

Skin swab samples were serially diluted using sterile brain heart infusion (BHI) broth, and 100 μL of sample was spread on BHI agar, BHI agar with 4 µg/mL furazolidone, BHI agar with 0.4 µg/mL clindamycin and BHI agar with 8 µg/mL clindamycin. Plates were incubated for 7--10 days under anaerobic conditions \[[@CR36]\]. After incubation, depending on bacterial growth and the number of putative *C. acnes* counts (minute white colonies), 1--10 colonies were subcultured into fresh BHI agar plates and incubated for a further 2 days. After incubation, 1--5 *C. acnes* characteristic colonies from each plate were tested for further identification. Each suspected colony was subjected to genomic DNA extraction, and further polymerase chain reaction (PCR) amplification was performed for species-level confirmation, identification of A2058G (*E. coli* numbering) mutations in the 23S rRNA gene by restriction enzyme digestion, and presence of the ermX gene by PCR. The presence of *C. acnes* in the samples was confirmed by amplification of the *C. acnes* 23S rRNA gene using species-specific primers. The colonies that successfully amplified and provided the expected band (646 bp) in agarose gel electrophoresis were confirmed as *C. acnes* (electronic supplementary Fig. 1a). The association of clindamycin-resistant *C. acnes* was determined by restriction enzyme digestion of 646 bp PCR product with the MboII restriction enzyme \[[@CR37]\]. It specifically recognises the point mutation A2058G (*E. coli* numbering) responsible for clindamycin resistance and cleaves the 646 bp product into two products (450 bp and 200 bp, respectively) (electronic supplementary Fig. 1b). Clindamycin resistance mediated by ermX was determined using ermX gene-specific primers (electronic supplementary Fig. 1c).

### Direct Quantification of Clindamycin-Resistant*C. acnes* Using the Real Time-Polymerase Chain Reaction Method {#Sec10}

The real time-PCR (RT-PCR) method was developed to quantify the number of clindamycin-resistant *C. acnes* present in acne samples. Genomic DNA was extracted from the samples directly and quantitative PCR (qPCR) amplification was performed using specific primers and fluorescence-labelled (FAM) minor groove binder (MGB) \[[@CR38]\] probes to specifically detect A2058G mutations in the 23S rRNA gene of *C. acnes* (electronic supplementary Fig. 2). Different cell densities of the clindamycin-resistant *C. acnes* strain (CCARM 9010) were used as standard for quantification of the bacterial load. Approximately 600 μL of swab sample and CCARM 9010 *C. acnes* strain (in different dilutions from 10^1^ to 10^8^ CFU/mL) were subjected to total bacterial genomic DNA extraction using a QIAGEN kit (Germantown, MD, USA) as per the manufacturer's instructions. Moreover, the genomic DNA was subjected to qPCR quantification using a fluorescence-labelled probe (FAM) and primers to enumerate the number of clindamycin-resistant *C. acnes* present in the sample \[[@CR38], [@CR39]\].

Results {#Sec11}
=======

Study Population {#Sec12}
----------------

Eighty subjects were screened for all study inclusion parameters and 19 subjects were finally enrolled in the trial. The study flowchart is shown in Fig. [1](#Fig1){ref-type="fig"}. All subjects completed the trial and were evaluated for safety and efficacy assessment. The enrolled subjects included both males (63.2%) and females (36.8%) in the 18--29 years age group, with a mean age of 21.8 years. Demographics of the subject population are shown in Table [1](#Tab1){ref-type="table"}.Fig. 1Subject flow diagram for investigator-initiated trial. Study period: 12 weeks; 6 November 2017 (date of first subject enrolled), 30 August 2018 (date of last subject completed)Table 1Demographics of the safety and efficacy populationCharacteristicsSafety and efficacy populationTotal number19Age, years Mean (SD)21.8 (3.2) Median21.0 Range18--29Sex Number of females (%)7 (36.8) Number of males (%)12 (63.2)*SD* standard deviation

Safety Assessments {#Sec13}
------------------

No occurrence of treatment-emergent AEs (TEAEs; local or systemic) or changes in vital signs, physical examinations and urinalysis were reported for any patients during the course of the entire study. A negligible number of LSRs (erythema, edema, scaling, stinging/burning, and pruritus/itching) were reported in the study subjects, with all LSRs being predominantly minimal in severity on all visits, from Visit 2 to Visit 5 (Table [2](#Tab2){ref-type="table"}). One instance of a moderate LSR was observed in a case of stinging/burning and scaling on Visit 2 but was not observed in subsequent visits.Table 2Summary of local skin reactions after application of VB-1953: safety of VB-1953LSR parametersVisit 2Visit 3Visit 4Visit 5BaselinePost (1 h)PrePrePreErythema 0: None0 (0.0)2 (10.5)0 (0.0)4 (21.1)0 (0.0) 1: Trace4 (21.1)5 (26.3)11 (57.9)14 (73.7)11 (57.9) 2: Mild15 (78.9)12 (63.2)8 (42.1)1 (5.3)8 (42.1) 3: Moderate0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0) 4: Severe0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Edema 0: None0 (0.0)0 (0.0)2 (10.5)10 (52.6)16 (84.2) 1: Trace10 (52.6)12 (63.2)16 (84.2)9 (47.4)3 (15.8) 2: Mild9 (47.4)7 (36.8)1 (5.3)1 (5.3)0 (0.0) 3: Moderate0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0) 4: Severe0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Scaling 0: None0 (0.0)2 (10.5)6 (31.6)8 (42.1)11 (57.9) 1: Trace11 (57.9)9 (47.4)10 (52.6)11 (57.9)8 (42.1) 2: Mild7 (36.8)8 (42.1)3 (15.8)0 (0.0)0 (0.0) 3: Moderate1 (5.3)0 (0.0)0 (0.0)0 (0.0)0 (0.0) 4: Severe0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Stinging/burning 0: None1 (5.3)2 (10.5)8 (42.1)13 (68.4)15 (78.9) 1: Mild16 (84.2)15 (78.9)11 (57.9)6 (31.6)4 (21.1) 2: Moderate2 (10.5)2 (10.5)0 (0.0)0 (0.0)0 (0.0) 3: Severe0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Pruritus 0: None8 (42.1)10 (52.6)6 (31.6)9 (47.4)10 (52.6) 1: Minimal11 (57.9)9 (47.4)13 (68.4)10 (52.6)9 (47.4) 2: Moderate0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0) 3: Severe0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Data are expressed as *n* (%)Number of subjects = 19*LSR* local skin reaction

Efficacy Assessments {#Sec14}
--------------------

There was marked improvement in both inflammatory and noninflammatory lesions after 12 weeks of VB-1953 (2%) topical application, from baseline (Fig. [2](#Fig2){ref-type="fig"}a, b). The mean inflammatory lesion count decreased from 34.4 ± 6.4 at baseline to 16.7 ± 9.0 at week 12, with a mean reduction from baseline of 53.1% (*p* \< 0.0001) (Fig. [2](#Fig2){ref-type="fig"}c). Similarly, for noninflammatory lesion count, the mean absolute value reduced from 39.4 ± 7.8 at baseline to 19.5 ± 10.0 at week 12, with a mean reduction from baseline of 52.2% (*p* \< 0.0001) (Fig. [2](#Fig2){ref-type="fig"}c).Fig. 2Efficacy of the application of VB-1953 topical gel (2%) for 12 weeks twice daily for acne patients with moderate to severe acne. Effect of the application of VB-1953 topical gel (2%) on acne **a** inflammatory and **b** noninflammatory lesion counts. The mean and SD are shown (*n* = 19). The mean absolute inflammatory lesion score decreased from 34.4 ± 6.4 at baseline to 16.7 ± 9.0 at week 12 (*p* \< 0.0001; two-tailed *t* test), whereas the noninflammatory lesion score decreased from 39.4 ± 7.8 at baseline to 19.5 ± 10.0 at week 12 (*p* \< 0.0001; two-tailed *t* test). **c** Percentage reduction of the inflammatory and noninflammatory count across different weeks (baseline and weeks 4, 8 and 12) during application of the VB-1953 topical gel (2%) formulation. **d** IGA scores (%) at baseline and week 12. The IGA score for severity of acne has been graded as 0: clear; 1: almost clear; 2: mild; 3: moderate; and 4: severe. *SD* standard deviation, *IGA* Investigator's Global Assessment

IGA success at week 12 after topical application of VB-1953 gel (2%) was 26.3%, where IGA success was defined as a score of 'clear' or 'almost clear' (IGA score of 0 or 1) and a grade 2 or higher IGA improvement from baseline. The number of subjects enrolled in the study who had moderate (IGA score of 3) or severe (IGA score of 4) acne at baseline was 18 and 1, respectively. At week 12, five subjects had an IGA score of 1 (almost clear), nine subjects had an IGA score of 2 (mild), and five subjects had an IGA score of 3 (moderate) (Fig. [2](#Fig2){ref-type="fig"}d). Overall, 31.6% and 47.1% of subjects exhibited a 2-point and 1-point improvement in IGA score, respectively, while 21.1% of subjects exhibited no change in IGA score compared with baseline at week 12.

Detection of Clindamycin-Resistant *C. acnes* Strains in Acne Samples Collected from Patients {#Sec15}
---------------------------------------------------------------------------------------------

*C. acnes* colonies were isolated from the samples collected from subjects and grown on BHI agar plates. Using the PCR method, the presence of the A2058G mutation on the 23S rRNA gene, and ermX gene detection in DNA extracted from the cells of *C. acnes* colonies, were performed. The MboII restriction enzyme specifically recognises and cleaves DNA when there is a A2058G mutation in the bacterial target. The presence of two specific bands on agarose gel electrophoresis following restriction conferred the presence of the aforesaid mutation, which is responsible for clindamycin resistance. Similarly, presence of the ermX gene in the *C. acnes* DNA, which is responsible for clindamycin resistance in the strain, was checked using ermX-specific primers (data not shown).

Analysis of acne swab samples collected from 80 subjects on Visit 1 (during initial screening) revealed the presence of clindamycin-resistant *C. acnes* strains in swab samples of 19 subjects. Of these, strains with the A2058G mutation in the 50S ribosomal subunit were identified in swab samples of 10 subjects, samples from 7 subjects had *C. acnes* isolates that were ermX gene-positive, and swab samples from two subjects exhibited *C. acnes* strains positive for both the above-mentioned features (Fig. [3](#Fig3){ref-type="fig"}a). At Visit 3 (week 4), acne samples from 10 of 19 subjects enrolled displayed the presence of clindamycin-resistant *C. acnes* strains; this number further decreased to 8 on Visit 5 (week 12) after topical application of VB-1953 gel.Fig. 3Effect of the topical application of VB-1953 (2%) gel on clindamycin-resistant strains associated with acne lesions. **a** Number of subjects harbouring resistant *C. acnes* at different weeks: initial screening date (Visit 1), week 4 after enrolment (Visit 3), and week 12 after enrolment (Visit 5). **b** Clindamycin-resistant *C. acnes* bacterial load (log CFU/mL) decreased at the initial screening date (Visit 1), week 4 after enrolment (Visit 3), and week 12 after enrolment (Visit 5). *C. acnes* Cutibacterium acnes, *CFU* colony-forming unit

Using RT-PCR, we estimated the number of clindamycin-resistant *C. acnes* strains in the acne samples. Figure [3](#Fig3){ref-type="fig"}b shows that the resistant *C. acnes* gradually decreased from log 4.9 CFU/mL on Visit 1 to log 3.6 CFU/mL on Visit 5, indicating a decrease in total resistant *C. acnes* by 94.3 ± 1.0% (*p* \< 0.05) after 4 weeks of topical application of VB-1953.

Discussion {#Sec16}
==========

With the emergence of resistance to the currently approved antibiotics in clinical isolates of *C. acnes,* there is an urgent requirement to look beyond the existing arsenal of anti-acne agents \[[@CR18], [@CR40]\]. While antimicrobials such as benzoyl peroxides are increasingly being used as an alternate choice \[[@CR41], [@CR42]\], clinical evidences show that such antimicrobials are maximally effective only when combined with antibiotics \[[@CR26], [@CR27]\]. Therefore, there is an unmet need for next-generation antibiotics that can retard the development of resistance, in addition to being effective against resistant strains of *C. acnes*. Antibiotics that are bactericidal in nature and can exert enhanced efficacy against *C. acnes* of varied resistance profiles, while mounting an anti-inflammatory effect to manage the host inflammation, could emerge as the next-generation treatment in the management of acne \[[@CR18]\]. Such an active antibiotic when delivered at optimum concentrations at the desired site can emerge as a powerful treatment of acne.

Fluoroquinolones are known for their anti-inflammatory properties, apart from their strong antibacterial action \[[@CR43]\]. Several evidences (both *in vivo* and *in vitro*) suggest the involvement of fluoroquinolones in the inhibition of LPS-induced tumour necrosis factor (TNF)-α and several interleukins, such as IL-1 and IL-6 production \[[@CR44], [@CR45]\]. One of the critical components in acne is host-mediated inflammation. *C. acnes* is known to induce inflammatory cytokine expression, including TNFα, IL-6, IL-8 and IL-12, in macrophages via activation of TLR-2 \[[@CR8]\]. The role of IL-6 in *C. acnes*-induced cell lines, such as macrophages, keratinocytes and sebocytes, has been shown in multiple reports \[[@CR8], [@CR46], [@CR47]\]. Alestas et al. found enhanced IL-6 expression in acne-involved skin \[[@CR48]\]. The IL-1 family of cytokines has been found to be associated with tissue damage in acne patients \[[@CR49]\]. VB-1953 was found to reduce dead *C. acnes*-induced inflammation in both in vitro and in vivo models. This action is independent of its bactericidal action. In vitro, VB-1953 significantly reduced IL-6 levels in the human monocyte cell line THP-1 \[[@CR31]\]. Furthermore, VB-1953 showed a dose-dependent reduction in messenger RNA (mRNA) expression of IL-1α, IL-1β, IL-6, IL-8 and IL-12 in THP-1 cells (unpublished data). VB-1953 formulation was also found to exert anti-inflammatory effects in a dead *C. acnes*-induced rat paw edema model (unpublished data).

In this study, we selected a bactericidal antibiotic, VB-1953, a fourth-generation fluoroquinolone that is potent across *C. acnes* having different resistance phylotypes \[[@CR18]\]. A topical formulation of VB-1953 showed a higher reduction in inflammatory lesion counts when applied once or twice daily compared with a pooled vehicle treatment group in a proof-of-concept clinical trial \[[@CR31]\]. In this study, we report that 2% VB-1953 was safe and well tolerated in moderate to severe acne patients with clindamycin-resistant *C. acnes*. Interestingly, there had been a significant decrease in both inflammatory and noninflammatory acne lesions within 12 weeks of application of the formulation, with a decrease in patients harbouring clindamycin-resistant *C. acnes* strains of 57.8% from baseline.

Of the 80 clindamycin nonresponder acne patients, 19 subjects were enrolled in the study after initial laboratory screening for the presence of clindamycin-resistant *C. acnes* on their acne lesion samples. This was one of the critical study criteria to evaluate the efficacy of the VB-1953 formulation in patients with clindamycin-resistant strains of *C. acnes*. Our data showed only 24% of the total subjects screened were associated with clindamycin-resistant *C. acnes*. It is possible that the remaining clindamycin nonresponder patients had additional etiologies that conferred the nonresponsive status; however, we only focused on those patients who met the dual criteria of clindamycin treatment failure together with harbouring clindamycin-resistant strains of *C. acnes.* It is possible that the percentage of this subset reflected the distribution in the population, verisimilar to the one in three patients reported in the US \[[@CR17]\]. Additionally, the low prevalence could also be due to the method of sample collection, insufficient sampling area, surface sampling, or failure of sufficient growth of *C. acnes* colonies. However, we believe that this is a large subset of the population that can benefit from an effective drug rather than being treated with an antibiotic that they are nonresponsive to.

Lincosamides (clindamycin) are known to inhibit bacterial protein synthesis by interacting 23S rRNA residues \[[@CR50]\] in a similar way to macrolides. A2058 (*E. coli* numbering) residue is one of the pivotal nucleotides for lincosamide binding at the bacterial target \[[@CR51]\]. Point mutation at A2058G in 23S rRNA is reported to confer high clindamycin resistance \[[@CR52]\]. Similarly, many reports indicate instances of ermX gene-mediated clindamycin and erythromycin resistance in *C. acnes* \[[@CR24]\]. In our case, 53% of the 19 recruited subjects showed presence of clindamycin-resistant *C. acnes* strains with the A2058G mutation, 37% of cases were ermX gene-positive, and the remaining 10% showed presence of both the A2058G mutation and the ermX gene on their skin. Topical application of VB-1953 for 12 weeks on all 19 patients with clindamycin-resistant strains in their skin decreased this number from 19 to 8. A decrease in resistant *C. acnes* count was also confirmed by RT-PCR. Over the 12-week treatment course, it was observed that the average colony count of resistant bacteria in the patient population was reduced by approximately 94% (*p* \< 0.05). VB-1953 efficacy in ameliorating inflammatory and noninflammatory lesions (*p* \< 0.001) in patients with acne lesions tested positive for clindamycin-resistant *C*. *acnes* offers an exciting clinical option for this subset of patients. It should be noted that these patients had not responded to clindamycin. Mechanistically, this could be attributed to the bactericidal action on a different target in *C. acnes*. Additionally, VB-1953 also exerts an immunomodulatory effect via decreasing proinflammatory cytokine-mediated inflammation (unpublished data). Taken together with the safety profile of VB-1953, our data strongly suggest that VB-1953 can emerge as the next-generation treatment for moderate to severe inflammatory acne, especially in the setting of clindamycin-resistant etiology. However, one of the major limitations of this study is that it was an open-label trial with a small sample size. A bigger, double-blinded study is warranted for conformation of the data with more than one clinical observer. Moreover, photographs of treated patients, if taken with proper consent, would have been helpful to support the efficacy of the treatment.

Conclusion {#Sec17}
==========

VB-1953 showcased good efficacy in treating both inflammatory and noninflammatory acne lesions without serious adverse effects. While larger studies are necessary to confirm these findings, our present data suggest VB-1953 as a future therapy against acne, even with an underlying resistant *C. acnes* etiology.
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